بدائل البحث:
decrease therapeutic » increased therapeutic (توسيع البحث), degrader therapeutics (توسيع البحث), great therapeutic (توسيع البحث)
host resistance » plant resistance (توسيع البحث)
a therapeutic » _ therapeutic (توسيع البحث), _ therapeutics (توسيع البحث), new therapeutic (توسيع البحث)
decrease host » decreases short (توسيع البحث)
يعرض 21 - 40 نتائج من 27,819 نتيجة بحث عن '(( ((decrease therapeutic) OR (a therapeutic)) research ) OR ( decrease host resistance ))', وقت الاستعلام: 0.97s تنقيح النتائج
  1. 21
    Figure S2 from Circadian Oscillations Persist in Cervical and Esophageal Cancer Cells Displaying Decreased Expression of Tumor-Suppressing Circadian Clock Genes

    Figure S2 from Circadian Oscillations Persist in Cervical and Esophageal Cancer Cells Displaying Decreased Expression of Tumor-Suppressing Circadian Clock Genes حسب Pauline J. van der Watt (15068109)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  2. 22
    Figure S4 from Circadian Oscillations Persist in Cervical and Esophageal Cancer Cells Displaying Decreased Expression of Tumor-Suppressing Circadian Clock Genes

    Figure S4 from Circadian Oscillations Persist in Cervical and Esophageal Cancer Cells Displaying Decreased Expression of Tumor-Suppressing Circadian Clock Genes حسب Pauline J. van der Watt (15068109)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  3. 23
    Figure 4 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma

    Figure 4 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma حسب Khaled Mohamed Nassar (19810317)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  4. 24
    Figure 2 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma

    Figure 2 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma حسب Khaled Mohamed Nassar (19810317)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  5. 25
    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis حسب Shaina F. Bruce (15091273)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  6. 26
    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis حسب Shaina F. Bruce (15091273)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  7. 27
    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis حسب Shaina F. Bruce (15091273)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  8. 28
    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis حسب Shaina F. Bruce (15091273)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  9. 29
    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis حسب Shaina F. Bruce (15091273)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  10. 30
    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis حسب Shaina F. Bruce (15091273)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  11. 31
    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis حسب Shaina F. Bruce (15091273)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  12. 32
    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis حسب Shaina F. Bruce (15091273)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  13. 33
    Supplemental Table 2 Phosphokinase Array from Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma

    Supplemental Table 2 Phosphokinase Array from Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocar... حسب Brittany L. Allen-Petersen (14935217)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  14. 34
    Supplemental Table 1 Kinase Inhibitor Screen from Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma

    Supplemental Table 1 Kinase Inhibitor Screen from Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Aden... حسب Brittany L. Allen-Petersen (14935217)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  15. 35
    Supplementary Data S1 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

    Supplementary Data S1 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance حسب Kristen Jensen-Pergakes (15090247)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  16. 36
    Supplementary Data S2 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

    Supplementary Data S2 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance حسب Kristen Jensen-Pergakes (15090247)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  17. 37
    Supplementary Data S3 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

    Supplementary Data S3 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance حسب Kristen Jensen-Pergakes (15090247)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  18. 38
    Supplementary Data from Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2<sup>+</sup> Breast Tumor Microenvironment

    Supplementary Data from Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2<sup>+</sup> Breast Tumor Microenvironment حسب Dimitrios N. Sidiropoulos (8812874)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  19. 39
    Supplementary Data from Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2<sup>+</sup> Breast Tumor Microenvironment

    Supplementary Data from Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2<sup>+</sup> Breast Tumor Microenvironment حسب Dimitrios N. Sidiropoulos (8812874)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  20. 40
    Supplementary Data from Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2<sup>+</sup> Breast Tumor Microenvironment

    Supplementary Data from Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2<sup>+</sup> Breast Tumor Microenvironment حسب Dimitrios N. Sidiropoulos (8812874)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: